Knockout of the ATPase inhibitory factor 1 protects the heart from pressure overload-induced cardiac hypertrophy

被引:22
|
作者
Yang, Kevin [1 ]
Long, Qinqiang [1 ,2 ,3 ]
Saja, Kamalamma [1 ,4 ]
Huang, Fengyuan [1 ]
Pogwizd, Steven M. [5 ]
Zhou, Lufang [5 ]
Yoshida, Masasuke [6 ]
Yang, Qinglin [1 ,2 ,3 ]
机构
[1] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Internal Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Hypertens, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[4] Univ Kerala, Dept Biochem, Thiruvananthapuram 695581, Kerala, India
[5] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA
[6] Kyoto Sangyo Univ, Dept Mol Biosci, Kyoto 6038555, Japan
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
基金
中国国家自然科学基金;
关键词
NF-KAPPA-B; MITOCHONDRIAL ATPASE; ACTIVATION; SYNTHASE; ATPIF1; F-1-ATPASE; RESOLUTION; AUTOPHAGY; GROWTH; ASSAYS;
D O I
10.1038/s41598-017-11251-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mitochondrial ATP synthase catalyzes the coupling of oxidative phosphorylation. Under pathological conditions, ATP synthase hydrolyzes ATP to replenish protons from the matrix into the intermembrane space, sustaining mitochondrial membrane potential. ATPase inhibitory factor 1 (IF1) is a nuclearen-coded, ATP synthase-interacting protein that selectively inhibits the hydrolysis activity of ATP synthase, which may render the protective role of IF1 in ischemic hearts. However, the in vivo cardiac function of IF1 and the potential therapeutic application targeting IF1 remain obscure. In the present study, we uncovered that IF1 is upregulated in mouse hearts with pressure overload-induced hypertrophy and in human hearts with dilated cardiomyopathy. IF1 knockout (KO) mice were protected against cardiac dysfunction and pathological development induced by transverse aortic constriction (TAC) or isoproterenol infusion. The reduced ATP hydrolysis activated AMPK activity in IF1 KO hearts, which together facilitated autophagy. These results suggest that IF1 upregulation in the failing heart may be a maladaptive response. Inhibiting IF1 in the hypertrophied heart not only prevents cell death from excessive mitochondrial depolarization but also activates AMPK signaling and increases autophagy. Therefore, IF1 inhibition may serve as a potential therapeutic target in treating pathological cardiac hypertrophy and heart failure.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Triptolide protects rat heart against pressure overload-induced cardiac fibrosis
    Zhang, Zhengang
    Qu, Xinkai
    Ni, Yue
    Zhang, Kai
    Dong, Zhifeng
    Yan, Xiaochen
    Qin, Jianhua
    Sun, Hongguang
    Ding, Yongling
    Zhao, Pei
    Gong, Kaizheng
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 2498 - 2505
  • [32] Senescent heart compared with pressure overload-induced hypertrophy
    Assayag, P
    Charlemagne, D
    deLeiris, J
    Boucher, F
    Valere, PE
    Lortet, S
    Swynghedauw, B
    Besse, S
    HYPERTENSION, 1997, 29 (01) : 15 - 21
  • [33] TMEM173 protects against pressure overload-induced cardiac hypertrophy by modulating autophagy
    Jin, Ya-Ge
    Zhou, Heng
    Fan, Di
    Che, Yan
    Wang, Zhao-Peng
    Wang, Sha-Sha
    Tang, Qi-Zhu
    JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (07) : 5176 - 5192
  • [34] Focal selective chemo-ablation of spinal cardiac afferent nerve by resiniferatoxin protects the heart from pressure overload-induced hypertrophy
    Wang, Deguo
    Wu, Yong
    Chen, Yueyun
    Wang, Ancai
    Lv, Kun
    Kong, Xiang
    He, Yang
    Hu, Nengwei
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 377 - 385
  • [35] Sarcoplasmic reticulum function in pressure overload-induced cardiac hypertrophy
    Yao, XH
    Cantor, E
    Vasanji, Z
    Greville, J
    Netticadan, T
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (04) : 636 - 636
  • [36] Ablation of TRPV1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy
    Zhong, Beihua
    Rubinstein, Jack
    Wang, Donna H.
    CIRCULATION, 2008, 118 (18) : S546 - S546
  • [37] Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis
    Tang, Chaoliang
    Yin, Guobing
    Huang, Chunxia
    Wang, Hongtao
    Gao, Jie
    Luo, Jianfeng
    Zhang, Zhetao
    Wang, Jiawu
    Hong, Junmou
    Chai, Xiaoqing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [38] Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
    Xu, Si-Chi
    Ma, Zhen-Guo
    Wei, Wen-Ying
    Yuan, Yu-Pei
    Tang, Qi-Zhu
    PPAR RESEARCH, 2017, 2017
  • [39] Diacylglycerol kinase ζ attenuates pressure overload-induced cardiac hypertrophy
    Harada, Mutsuo
    Takeishi, Yasuchika
    Arimoto, Takanori
    Niizeki, Takeshi
    Kitahara, Tatsuro
    Goto, Kaoru
    Walsh, Richard A.
    Kubota, Isao
    CIRCULATION JOURNAL, 2007, 71 (02) : 276 - 282
  • [40] Oral sophocarpine protects rat heart against pressure overload-induced cardiac fibrosis
    Li, Jun
    Li, Liudong
    Chu, Hongxia
    Sun, Xiaojian
    Ge, Zhiming
    PHARMACEUTICAL BIOLOGY, 2014, 52 (08) : 1045 - 1051